Eurofins Viracor Launches Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

Published on: 
BP Elements, BioPharm International's BP Elements, March 2023, Volume 2, Issue 3

Eurofins Viracor ExPeCT CAR-T qPCR assay is a tool designed for monitoring and optimizating CAR-T therapies.

Eurofins Viracor, a Eurofins company specializing in testing for infectious diseases, immunology, and allergy, launched in February 2023 its Viracor ExPeCT chimeric antigen receptor T-cell (CAR-T) multiplexed quantitative real-time polymerase chain reaction (qPCR) assay. The tool is designed to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.

According to a press release from Feb. 16, 2023, the test is designed to provide clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient’s body, in turn offering potential insights into therapy effectiveness and what future treatment options may be advisable.


Source: Eurofins